Semaglutide vs mazdutide: evidence, cost, and legality

Which is better, semaglutide or mazdutide?

On the trial evidence alone, mazdutide produced more weight loss and slightly more HbA1c lowering than semaglutide 1 mg in DREAMS-3, although that result is so far a manufacturer topline announcement and the semaglutide dose was the diabetes dose, not the 2.4 mg obesity dose. For anyone in the United States the practical answer is semaglutide: it is FDA approved, has completed cardiovascular outcomes trials, and can be prescribed, whereas mazdutide is approved only by China's regulator and cannot lawfully be compounded or sold in the United States. [1] [2] [3] [4] [5] [6]

How do semaglutide and mazdutide compare?

Semaglutide and Mazdutide compared by dimension
Dimension	Semaglutide	Mazdutide
Head-to-head evidence [1] [2]	Semaglutide 1 mg weekly: 21.0% reached HbA1c under 7% plus at least 10% weight loss; HbA1c fell 1.84 points and weight 6.0% at 32 weeks in DREAMS-3.	Mazdutide 6 mg weekly: 48.0% reached the composite goal; HbA1c fell 2.03 points and weight 10.3% at 32 weeks in DREAMS-3.
Note: DREAMS-3 was open label and enrolled 349 Chinese adults with type 2 diabetes of 10 years or less and a BMI of 28 or higher. Results come from the manufacturer's October 2025 release; the design paper is indexed, the full results were not found in PubMed on the verification date.
Mechanism [7] [8]	Selective GLP-1 receptor agonist.	Dual GLP-1 and glucagon receptor agonist (oxyntomodulin analog); glucagon receptor activity adds energy expenditure and liver fat oxidation.
Placebo-controlled weight loss [8] [9] [10]	14.9% versus 2.4% on placebo at 68 weeks with 2.4 mg in STEP 1 (1,961 adults).	11.0% and 14.0% at 4 and 6 mg versus 0.3% gain on placebo at 48 weeks in GLORY-1 (610 Chinese adults); 18.1% at 16 mg versus 0.9% at 32 weeks in a US phase 2 trial (179 adults).
Note: Different populations, doses, and durations; the direct trial above is the better guide.
Cardiovascular outcomes [3] [4] [8]	SELECT: 20% relative reduction in major adverse cardiovascular events (hazard ratio 0.80) in 17,604 adults with obesity and cardiovascular disease; SUSTAIN-6: hazard ratio 0.74 in type 2 diabetes.	No cardiovascular outcomes trial has reported.
Regulatory status [5] [6] [7] [11] [12]	FDA approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021). The shortage-based compounding allowance ended in 2025.	Approved in China for chronic weight management (June 2025) and type 2 diabetes (September 2025). Not FDA approved, not on the 503A bulks list, and not lawfully compounded or sold in the United States.
WADA status [5] [13]	Not on the WADA Prohibited List.	Not named on the list. Because it is approved in China, section S0 (non-approved substances) may not apply; athletes should confirm with their anti-doping organization.
Side effects [1] [7] [9] [14]	Nausea 44%, diarrhea 32%, vomiting 24%, constipation 24% at 2.4 mg in STEP 1; boxed warning for thyroid C-cell tumors.	Diarrhea 36%, decreased appetite 29%, nausea 23%, vomiting 14% in the type 2 diabetes phase 2 trial; gastrointestinal events mostly mild to moderate in DREAMS-3. No US label, so no boxed warning has been issued.
Route and dosing [7] [8] [10] [15]	Once weekly injection (0.25 mg escalated to 2.4 mg for weight, up to 2 mg for diabetes) or a once daily tablet.	Once weekly injection; trial maintenance doses of 4 or 6 mg (GLORY-1) and up to 16 mg in the US phase 2 trial. No approved US label.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Semaglutide and Mazdutide: grade, status, and cost
Attribute	Semaglutide	Mazdutide
Class	GLP-1 receptor agonist (31 amino acid analog of human GLP-1, acylated for once weekly dosing)	Dual agonist of the GLP-1 and glucagon receptors (oxyntomodulin analog, acylated, once weekly)
What it is	FDA approved GLP-1 agonist with about 15% average weight loss in a 68 week RCT and proven cardiovascular benefit.	GLP-1/glucagon dual agonist with 14% weight loss at 48 weeks in a Chinese phase 3 trial and 18% at 16 mg in a US phase 2; not FDA approved.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: Not eligible for compounding
Compounding	FDA approved products (Ozempic 2017, Rybelsus 2019, Wegovy 2021). FDA removed semaglutide from the drug shortage list on February 21, 2025; compounding by 503A pharmacies had to stop by April 22, 2025 and by 503B outsourcing facilities by May 22, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit GLP-1 products and salt forms (semaglutide sodium, semaglutide acetate) that are not the approved active ingredient. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.	Not FDA approved as of the last verification date. Because mazdutide is not a component of an FDA approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded or dispensed in the United States, and any product sold as mazdutide in the US is an unapproved drug. Its development and registration have centered on China, where the national drug regulator approved it for chronic weight management in adults (June 2025) and for type 2 diabetes (September 2025); those approvals do not make it legal to sell or compound in the US.
WADA	WADA: Not WADA prohibited	WADA: WADA status unclear
Routes	Subcutaneous injection once weekly (Ozempic, Wegovy), Oral tablet once daily (Wegovy tablets, Ozempic tablets, Rybelsus)	Subcutaneous injection once weekly
Typical cost	Manufacturer list price is 1,349.02 USD per month for Wegovy and 1,027.51 USD for Ozempic (checked 2026-09-22), falling to 675 USD for both on January 1, 2027. Manufacturer self-pay prices run 149 to 499 USD per month by product and dose, with the Wegovy pen at 349 USD. With commercial insurance the manufacturer savings offer can bring a covered prescription to 25 USD per month, and eligible Medicare Part D enrollees pay 50 USD per month for Wegovy under the Medicare GLP-1 Bridge (July 2026 to December 2027). A 2024 study found compounded semaglutide at a median 231 USD for the first month during the shortage; compounding is now limited to patient specific needs.	Not available through licensed channels in the United States. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 27, 2026	Sep 27, 2026

Has semaglutide been tested directly against mazdutide?

Direct comparisons of Semaglutide and Mazdutide
Study	Design and population	Outcome	Grade
Mazdutide versus semaglutide for the treatment of type 2 diabetes and obesity: rationale, design and baseline data of the DREAMS-3 phase 3 trial2026 PMID 41260459	Randomized, open label, active controlled phase 3 trial, 32 weeks plus 24 week extension (design and baseline paper)n = 349 Chinese adults with type 2 diabetes of 10 years or less and BMI 28 or higher	Design and baseline only; results pending publication. Topline figures are in the head-to-head evidence row, cited to the manufacturer announcement.	Evidence: Human RCT evidence

What do semaglutide and mazdutide cost?

Typical cost of Semaglutide and Mazdutide
Dimension	Semaglutide	Mazdutide
Typical cost	$149 to $1,349 per month	Not available through licensed channels in the United States. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Semaglutide price by channel	Price index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is mazdutide stronger than semaglutide?

In DREAMS-3, the one direct trial, mazdutide 6 mg produced 10.3% weight loss versus 6.0% with semaglutide 1 mg at 32 weeks and lowered HbA1c by 2.03 versus 1.84 points, per the manufacturer's topline release. The trial used the diabetes dose of semaglutide, not the 2.4 mg obesity dose. [1] [2]

Can I get mazdutide in the United States?

No lawful path exists outside a registered clinical trial. Mazdutide is not FDA approved, is not on the 503A bulks list, and cannot be compounded; it is approved only in China. [5] [6]

Does mazdutide protect the heart like semaglutide?

Unknown. Semaglutide reduced major cardiovascular events by 20% in SELECT and 26% in SUSTAIN-6. No cardiovascular outcomes trial of mazdutide has reported. [3] [4]

Do they have the same side effects?

Both mainly cause gastrointestinal effects. Semaglutide caused nausea in 44% in STEP 1; mazdutide caused diarrhea in 36% and nausea in 23% in its type 2 diabetes phase 2 trial. Only semaglutide has an FDA label with the thyroid C-cell boxed warning, because mazdutide has no US label. [7] [9] [14]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Semaglutide vs mazdutide: evidence, cost, and legality. https://peptideagent.ai/compare/semaglutide-vs-mazdutide
HTML link: <a href="https://peptideagent.ai/compare/semaglutide-vs-mazdutide">Semaglutide vs mazdutide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Semaglutide vs mazdutide

The short answer